STAAR Surgical's (STAA) EVO Visian Toric ICL Approved in Canada
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
STAAR Surgical Company (Nasdaq: STAA) was notified yesterday of the approval of its EVO Visian Toric ICL, STAAR's Implantable Collamer® Lens, for distribution in Canada by the Medical Devices Bureau of Health Canada.
With extensive clinical experience globally, the EVO and EVO Toric ICL is STAAR's next-generation lens implanted in the eye that works with the patient's natural eye to correct vision. Over 40% of STAAR's EVO ICL sales globally are Toric models. Unlike traditional contact lenses that are placed on the surface of the eye, the EVO Toric ICL is positioned inside the eye between the iris and the natural lens where it stays indefinitely.
"We are very pleased with Health Canada's approval that allows us to offer the EVO Toric ICL for myopia and astigmatism, with a broad spherical power range of -3.0 to -18.0 diopters and cylinder power range of 1.0 to 6.0 diopters, to our surgeons and their patients in Canada. This represents an important new option for eligible patients between 21 and 45 years old living with nearsightedness and astigmatism treated in a single procedure. This approval reinforces our deep commitment to patients seeking visual freedom, as we continue to expand our EVO ICL portfolio globally. STAAR looks forward to training Canadian surgeons on the EVO Toric ICL at the upcoming American Academy of Ophthalmology (AAO) 2016 Annual Meeting in Chicago in October, then bringing this visual freedom choice to the Canadian refractive surgery market," said Caren Mason, President and CEO.
The EVO and EVO Toric ICL has an extensive clinical history of safety and effectiveness. The EVO and EVO Toric ICL, with its central hole, offers premium refractive outcomes with efficiency and comfort for both the patient and the surgeon by eliminating the extra surgical step of the peripheral iridotomy. Over 200,000 lenses from the EVO ICL product family have been implanted globally to date. Clinical data show that the EVO ICL provides outstanding, predictable correction of high degrees of refractive errors, with the vast majority of patients achieving and maintaining 20/20 or better visual acuity through five years of follow up.1 Review of the peer-reviewed published literature demonstrates an excellent safety profile: specifically, eight studies including data from 1,291 eyes followed for up to five years describe a zero incidence of significant complications.2
Shimizu K, Kamiya K, Igarashi A, Kobashi H. Long-Term Comparison of Posterior Chamber Phakic Intraocular Lens With and Without a Central Hole (Hole ICL and Conventional ICL) Implantation for Moderate to High Myopia and Myopic Astigmatism. Medicine. 2016 Apr;95(14):e3270.
Packer M. Meta-Analysis and Review: Effectiveness, Safety and Central Port Design of the Intraocular Collamer Lens (ICL). In press.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EQT Corp. (EQT) Tops Q3 EPS by 15c; Announces CEO Succession
- Vertex Pharma (VRTX) Announces Positive Longer-Term ORKAMBI + KALYDECO Data in CF Progression Modification
- Marathon Petroleum (MPC) Misses Q3 EPS Views; Announces Strategic Plans to Unlock Shareholder Value
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!